VAL001
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2Active
Key Facts
About Respiratorius
Respiratorius is a clinical-stage biotech company based in Lund, Sweden, developing VAL001, a drug candidate for diffuse large B-cell lymphoma (DLBCL). The company has reported promising Phase I/IIa data showing improved two-year survival and operates a partnership-centric business model to de-risk development. Led by a board and CEO with strong pharmaceutical and financial expertise, Respiratorius is positioned to advance its lead program through further clinical development and potential out-licensing.
View full company profileTherapeutic Areas
Other Diffuse Large B-cell Lymphoma (DLBCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| Selinexor (XPOVIO®) | Karyopharm Therapeutics | Approved/Commercial |